Sera Prognostics (SERA) Preferred Stock Liabilities (2020 - 2021)
Sera Prognostics (SERA) posted Preferred Stock Liabilities of $149.1 million for Q2 2021, up 34.97% on a QoQ basis from $110.5 million in Q1 2021, and up 91.59% year-over-year from $77.8 million in Q2 2020.
Sera Prognostics (SERA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Sera Prognostics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $149.1 million for Q2 2021.
- Quarterly Preferred Stock Liabilities rose 91.59% year-over-year to $149.1 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $149.1 million (up 91.59% YoY) and the FY2020 annual result came in at $474000.0, changed N/A from the prior year.
- Preferred Stock Liabilities was $149.1 million for Q2 2021 at Sera Prognostics, up from $110.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $149.1 million in Q2 2021 and bottomed at $474000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.89 Bn | 173.59 Bn | 6.27 Bn | - |
| 2 | Stryker | 127.82 Bn | 124.94 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.49 Bn | 98.27 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.24 Bn | 65.78 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.02 Bn | 44.34 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.25 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 28.17 Bn | 25.89 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.72 Bn | 26.14 Bn | - | - |
| 9 | Koninklijke Philips | 25.31 Bn | 22.19 Bn | 2.07 Bn | - |
| 10 | Sera Prognostics | 103.03 Mn | 103.03 Mn | -28,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 149.14 Mn |
| Mar 31, 2021 | 110.50 Mn |
| Dec 31, 2020 | 474,000.00 |
| Sep 30, 2020 | 77.84 Mn |
| Jun 30, 2020 | 77.84 Mn |